Background and Purpose-The mechanisms of ischemic stroke in young adults are poorly understood. During the last years, several studies suggested a role for genetic factors predisposing to thrombophilia and for moderate hyperhomocysteinemia in this setting. Methods-We evaluated in 132 consecutive patients (66 males, 66 females; meanϮSD age, 38.4Ϯ11.7 years; meanϮSD age at first event, 34.8Ϯ10.9 years; range, 6 months to 50 years) referred to our center between January 1997 and December 1999 for a history of young adult ischemic stroke (age at first event, Ͻ51 years) the prevalence of factor V (FV) Leiden, prothrombin (FII) G20210A, and C677T and 5,10-methylenetetrahydrofolate reductase (MTHFR) gene mutations and fasting serum total homocysteine levels.
Background-Severe hyperhomocysteinemia due to cystathionine -synthase deficiency (CSD) is associated with early atherothrombotic vascular disease. Homocysteine may exert its effects by promoting oxidative damage. In the present study, we investigated whether in vivo formation of 8-iso-prostaglandin (PG) F 2␣ , a platelet-active product of arachidonic acid peroxidation, is enhanced in CSD and whether it correlates with in vivo platelet activation, as reflected by thromboxane (TX) metabolite excretion. Methods and Results-Urine and blood samples were obtained from patients with homozygous CSD (nϭ13) and age-matched healthy subjects. Urinary 8-iso-PGF 2␣ excretion was significantly higher in CSD patients than in control subjects (640Ϯ384 versus 213Ϯ43 pg/mg creatinine; Pϭ0.0015) and correlated with plasma homocysteine (ϭ0.398, Pϭ0.0076). Similarly, urinary 11-dehydro-TXB 2 excretion was enhanced in CSD (1166Ϯ415 versus 324Ϯ72 pg/mg creatinine; Pϭ0.0015) and correlated with urinary 8-iso-PGF 2␣ (ϭ0.362, Pϭ0.0153). Vitamin E supplementation (600 mg/d for 2 weeks) was associated with a statistically significant increase in its plasma levels (from 16.6Ϯ4.6 to 40.4Ϯ8.7 mol/L, Pϭ0.0002) and with reductions in 8-iso-PGF 2␣ (from 790Ϯ159 to 559Ϯ111 pg/mg creatinine, Pϭ0.018) and 11-dehydro-TXB 2 (from 1273Ϯ383 to 913Ϯ336 pg/mg creatinine, Pϭ0.028). A statistically significant inverse correlation was found between urinary 8-iso-PGF 2␣ and plasma vitamin E levels (ϭϪ0.745, Pϭ0.0135). Conclusions-The results of the present study suggest that enhanced peroxidation of arachidonic acid to form bioactive F 2 -isoprostanes may represent an important mechanism linking hyperhomocysteinemia and platelet activation in CSD patients. Moreover, they provide a rationale for dose-finding studies of vitamin E supplementation in this setting.
Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. Materials and Methods: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. Results: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). Conclusions: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.